|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
By Industry | By Industry Segment | By Services and Suppliers
| By Location
| By Hotbed |
Profile Search
|
Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury
New Jersey
08512
U.S.A.
Phone:
609-662-2000
Fax:
609-662-2807
|
Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing novel, first-in-class, small molecules called pharmacological chaperones, to treat human genetic diseases, including lysosomal storage diseases. The Company’s lead pharmacological chaperone migalastat HCl is in Phase 3 as a monotherapy for Fabry disease. Amicus and its partner GlaxoSmithKline Plc (GSK) are conducting Phase 3 registration studies of migalastat HCl for the treatment of Fabry disease. A Phase 3 study intended to support approval of migalastat HCl in the United States is fully enrolled and results are anticipated in the third quarter of 2012. Additionally, Amicus and GSK are currently conducting a separate Phase 3 study intended to further support global registration of migalastat HCl.
Amicus continues to advance its program evaluating the use of pharmacological chaperones in combination with enzyme replacement therapy (ERT) as an expansion of the chaperone technology platform. Two chaperone-ERT combinations, migalastat HCl co-administered with ERT for Fabry disease and AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, are currently in Phase 2 development. The Company is also investigating chaperone-ERT combinations for Gaucher disease in preclinical studies.
Amicus also has a preclinical pipeline of pharmacological chaperones for diseases of neurodegeneration, including AT3375 for Parkinson’s disease. The Company has broad, issued intellectual property around the methods, use, and composition of pharmacological chaperones to treat genetic diseases and diseases of neurodegeneration. In addition to the currently issued patents, Amicus has several patent applications pending.
Email:
info@amicustherapeutics.com
Ownership:
Public
Web Site:
Amicus Therapeutics, Inc.
Employees:
100
Symbol: FOLD
|
|
|
Company News |
Amicus Therapeutics, Inc. (FOLD) to Present at UBS Global Healthcare Conference
5/14/2013 9:05:11 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) to Announce Full-Year 2012 Financial Results on March 12, 2013
3/7/2013 11:42:12 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) Introduces Proprietary "CHART" Platform Technology
3/4/2013 11:36:04 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) Presents Additional 6-Month Results From Phase 3 Fabry Monotherapy Study at LDN World Symposium
2/15/2013 7:04:28 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease
2/14/2013 11:12:55 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) Provides Full-Year 2013 Financial Guidance and Strategic Outlook
1/7/2013 9:40:16 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) Rises on Positive Pompe Disease Data
1/4/2013 7:50:54 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) to Present at 31st Annual J.P. Morgan Healthcare Conference
1/3/2013 9:09:10 AM
More...
|
Amicus Therapeutics, Inc. (FOLD), GlaxoSmithKline (GSK) Say Treatment Misses Goal
12/20/2012 7:38:25 AM
More...
|
Amicus Therapeutics, Inc. (FOLD) to Present at Lazard Capital Markets' Healthcare Conference
11/13/2012 9:02:29 AM
More...
|
|
|
|
 |
|
|
|
|
|
|
|
|
|